BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10358701)

  • 1. 131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status.
    Tepmongkol S; Heyman S
    Med Pediatr Oncol; 1999 Jun; 32(6):427-31; discussion 432. PubMed ID: 10358701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroblastoma therapy using radiolabelled [131I]meta-iodobenzylguanidine ([131I]MIBG) in combination with other agents.
    Mairs RJ
    Eur J Cancer; 1999 Aug; 35(8):1171-3. PubMed ID: 10615225
    [No Abstract]   [Full Text] [Related]  

  • 3. Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy.
    Streby KA; Shah N; Ranalli MA; Kunkler A; Cripe TP
    Pediatr Blood Cancer; 2015 Jan; 62(1):5-11. PubMed ID: 25175627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear medicine therapy of neuroblastoma.
    Hoefnagel CA
    Q J Nucl Med; 1999 Dec; 43(4):336-43. PubMed ID: 10731784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [131I]MIBG radionuclide therapy in carcinoid syndrome.
    Taal BG; Zuetenhorst H; Valdés Olmos RA; Hoefnagel CA
    Eur J Surg Oncol; 2002 Apr; 28(3):243. PubMed ID: 11944956
    [No Abstract]   [Full Text] [Related]  

  • 6. [131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma.
    McCluskey AG; Boyd M; Gaze MN; Mairs RJ
    Cancer Lett; 2005 Oct; 228(1-2):221-7. PubMed ID: 15935554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
    Kang TI; Brophy P; Hickeson M; Heyman S; Evans AE; Charron M; Maris JM
    J Pediatr Hematol Oncol; 2003 Oct; 25(10):769-73. PubMed ID: 14528098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of 131I-MIBG in high-risk neuroblastoma treatment.
    Lessig MK
    J Pediatr Oncol Nurs; 2009; 26(4):208-16. PubMed ID: 19726792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma.
    Sato Y; Kurosawa H; Fukushima K; Okuya M; Hagisawa S; Sugita K; Arisaka O; Inaki A; Wakabayashi H; Nakamura A; Fukuoka M; Kayano D; Kinuya S
    Ital J Pediatr; 2012 Oct; 38():53. PubMed ID: 23067429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of neuroblastoma with [131I]MIBG at diagnosis.
    Troncone L; Rufini V; Luzi S; Mastrangelo R; Riccardi R
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):65-8. PubMed ID: 9002753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts.
    Rutgers M; Buitenhuis CK; van der Valk MA; Hoefnagel CA; Voûte PA; Smets LA
    Int J Cancer; 2000 Dec; 90(6):312-25. PubMed ID: 11180134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
    Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
    J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma.
    Gaze MN; Gains JE; Walker C; Bomanji JB
    Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):66-78. PubMed ID: 23474636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.
    Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; de Kraker J; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I
    Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 11315605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients.
    Garaventa A; Bellagamba O; Lo Piccolo MS; Milanaccio C; Lanino E; Bertolazzi L; Villavecchia GP; Cabria M; Scopinaro G; Claudiani F; De Bernardi B
    Br J Cancer; 1999 Dec; 81(8):1378-84. PubMed ID: 10604736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined use of chemotherapy and 131I-metaiodobenzylguanidine in the treatment of advanced-stage neuroblastoma.
    Sari O; Uğur O; Emir S; Akyüz C
    Turk J Pediatr; 2001; 43(1):29-33. PubMed ID: 11297155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [131I]MIBG as a first line treatment in advanced neuroblastoma.
    Hoefnagel CA; De Kraker J; Valdés Olmos RA; Voûte PA
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):61-4. PubMed ID: 9002752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
    Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R
    Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary ovarian insufficiency in children after treatment with 131I-metaiodobenzylguanidine for neuroblastoma: report of the first two cases.
    Clement SC; Kraal KC; van Eck-Smit BL; van den Bos C; Kremer LC; Tytgat GA; van Santen HM
    J Clin Endocrinol Metab; 2014 Jan; 99(1):E112-6. PubMed ID: 24187404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with meta-[131I]iodobenzylguanidine and cisplatin in stage IV neuroblastoma.
    Mastrangelo S; Tornesello A; Diociaiuti L; Riccardi R; Rufini V; Troncone L
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):69-71. PubMed ID: 9002754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.